Smart-4-Fabry has been conceived and created to obtain a new nanoformulation of GLA, that will improve the efficacy and toleration compared to the actual treatment with non-formulated GLA. The final benefit will be seen as considerable reduction on the Fabry disease treatment cost and a substantial improvement in the life-quality of Fabry disease patients.
Smart-4-Fabry will impact on a major health problem, the existence of new therapies for rare diseases, which constitutes a priority societal challenge as shown in the H2020 Work Programmes. Rare diseases, like Fabry disease, mean a major health problem for a significant number of people in total, but affecting small number of patients for each individual disease.
This workshop will take place on 3rd February at 14:00h.
Join the Smart4Fabry Final Workshop to learn from expert speakers how, why and for what the solution proposed by Smart4Fabry was conceived, a sign of cooperation at European level to boost nanomedicine development and translation to clinical stages.